by Isogenica Webmaster | Sep 2025 | Blogs
NGS in Antibody Discovery: How Deep is Your Sequence? Next-generation sequencing (NGS) has revolutionized antibody discovery by enabling high-depth analysis of diverse libraries, surpassing the limitations of traditional methods like Sanger sequencing. This article...
by Isogenica Webmaster | Jul 2025 | Blogs
Unlocking Hard-to-Drug Targets: How VHH Antibodies Overcome Drug Discovery Barriers For decades, certain drug targets have been labeled as “undruggable” due to their complex structures, lack of accessible binding sites, or dynamic conformational changes....
by Isogenica Webmaster | May 2025 | Blogs
A Competitive and Ethical Future in Discovery Pharmaceutical and biotech R&D is undergoing a notable shift in how therapeutic antibodies are discovered. Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise...
by Isogenica Webmaster | May 2025 | Blogs
Isogenica named in Business Weekly’s Ones2Watch In Q1 2025, Business Weekly published its latest Killer50 showcase – a long-standing benchmark for innovation in UK life sciences Recognition in a Difficult Quarter In Q1 2025, Business Weekly...
by Isogenica Webmaster | May 2025 | Blogs, Research Blogs
Building the next generation of precision oncology medicines Biologic therapies have reshaped oncology, but they come with real limitations. Traditional monoclonal antibodies are large, complex molecules that can struggle with tumor penetration, slow development...
by Isogenica Webmaster | Apr 2025 | Blogs, Research Blogs
Avoiding Freedom-to-Operate Pitfalls in Antibody Discovery In antibody discovery, identifying a promising therapeutic candidate is only part of the challenge, and even that is no easy task. For well-established drug targets, securing freedom-to-operate (FTO) is...